Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

2016 • 29,943 citations

Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review

2017 • 14,809 citations

The blockade of immune checkpoints in cancer immunotherapy

2012 • 12,062 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

2012 • 11,574 citations

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

2012 • 7,361 citations

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

2011 • 5,649 citations

Oncology Meets Immunology: The Cancer-Immunity Cycle

2013 • 5,543 citations

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

2015 • 5,526 citations

PD-1 and Its Ligands in Tolerance and Immunity

2008 • 4,838 citations

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

2014 • 4,720 citations

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

2002 • 4,625 citations

The immune contexture in human tumours: impact on clinical outcome

2012 • 4,275 citations

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

2013 • 3,290 citations

Molecular mechanisms of T cell co-stimulation and co-inhibition

2013 • 2,651 citations

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

2014 • 2,525 citations

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

2014 • 2,174 citations

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

2014 • 2,071 citations

Inhibitory B7-family molecules in the tumour microenvironment

2008 • 1,511 citations

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8⁺T lymphocytes are prognostic factors of human ovarian cancer

2007 • 1,317 citations

Tissue expression of PD-L1 mediates peripheral T cell tolerance

2006 • 1,145 citations

Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

2007 • 843 citations

Automated subcellular localization and quantification of protein expression in tissue microarrays

2002 • 764 citations

Programmed death ligand-1 expression in non-small cell lung cancer

2013 • 729 citations

B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

2004 • 664 citations

Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma

2010 • 632 citations

PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells

2003 • 584 citations

The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors

2006 • 570 citations

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

2010 • 554 citations

Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

2006 • 474 citations

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

2006 • 470 citations

Objective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer

2015 • 367 citations

<scp>PD</scp>‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐<scp>PD</scp>‐1/<scp>PD</scp>‐<scp>L</scp>1 clinical trials

2014 • 366 citations

The B7 Family and Cancer Therapy: Costimulation and Coinhibition

2007 • 326 citations

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

2023 • 216 citations

A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors.

2013 • 192 citations

Yin–Yang of costimulation: crucial controls of immune tolerance and function

2009 • 145 citations

Immunotherapy in the treatment of non-small cell lung cancer

2014 • 108 citations

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8[+] T lymphocytes are prognostic factors of human ovarian cancer

2009 • 87 citations

Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).

2014 • 64 citations

Therapeutic targeting of B7-H1 in breast cancer

2011 • 39 citations

[Expression and significance of gp96 and immune-related gene CTLA-4, CD8 in lung cancer tissues].

2010 • 9 citations